Industries / Frontier science / Longevity
Consumer clinics
This work sells checkups, tests and treatments meant to slow aging directly to the public, usually for cash and outside public health insurance.
7
Milestones achieved, from 1931 to 2020.
1
To watch for: announced, not yet confirmed outside.
2
Open deliverables. Nobody has shipped them.
The road
AchievedWatch forOpen
Achieved
1931
Lamb cells sold as youth
In 1931 the Swiss surgeon Paul Niehans developed what he called cellular therapy: injections of cells from lamb embryos, which he said would slow aging. By 1971 his 26-bed Clinique Générale La Prairie at Clarens, near Montreux, charged US$128 a shot and US$1,200 for a series of ten, and Niehans claimed more than 50,000 injections. Pierre Rentchnick, a Geneva cancer specialist and editor of the Swiss journal Médecine et Hygiène, called him a charlatan and pointed out that the body destroys the injected cells.
LessonNiehans would not discuss the science with critics, and demand rested on famous patients' word.
Credit
Paul Niehans; reported by Nada Skerly for the Alicia Patterson Foundation, 1971
1951
Patient tourists in Bucharest
From 1951 Ana Aslan ran Romania's Bucharest Geriatrics Institute, where older patients were injected with Gerovital H3, a product based on procaine, the anesthetic dentists use. By 1971 Romania's ministries of health, tourism and trade sold two-week "patient-tourist" trips for about US$400 including flights, and the state trading company Imeco put Gerovital exports at US$6 million to US$7 million a year. The US Food and Drug Administration (FDA) did not allow it to be imported.
Credit
Ana Aslan and the Romanian state; reported by Nada Skerly, 1971
2000
Fresh-cell ban struck down
In March 1997 Germany's health ministry made it a crime to use "fresh cells" in medicines for injection or infusion. Doctors who ran private sanatoriums and injected their patients with cells taken from sheep fetuses challenged the ban. On 16 February 2000 the Federal Constitutional Court declared it void, because federal law covers medicines put on the market, not medicines a doctor makes for the doctor's own patients. The court did not rule on whether the treatment was safe.
Lessona ban made under the wrong legal power fails, whatever the medical case for it.
Credit
Federal Constitutional Court of Germany (Bundesverfassungsgericht), First Senate, case 1 BvR 420/97
2015
A US$25,000 health scan
Human Longevity Inc. (HLI) was announced on 4 March 2014 by J. Craig Venter, Robert Hariri and Peter Diamandis, with US$70 million from investors and a plan to sequence up to 40,000 human genomes a year. In October 2015 it opened its first Health Nucleus in La Jolla, California, which combined a person's whole genome with whole-body MRI, heart ultrasound, a bone scan and blood tests. Quartz reported the price as US$25,000, aimed at self-insured executives and athletes, and quoted the cardiologist Rita Redberg of the University of California, San Francisco: there was "absolutely no evidence that any of those tests have any benefit for healthy people".
Credit
Human Longevity Inc.; J. Craig Venter
2016
Stem cell sellers counted
Leigh Turner of the University of Minnesota and Paul Knoepfler of the University of California, Davis searched the internet for US businesses advertising stem cell treatments that the FDA had not approved. They found 351 companies at 570 clinics, selling for conditions that included aging skin. Turner's recount in March 2021 found 1,480 businesses running 2,754 clinics, more than four times as many businesses as five years before.
Lessoncounting sellers from their own advertising is cheap and can be repeated, which is how the growth was seen.
Credit
Leigh Turner and Paul Knoepfler, Cell Stem Cell (2016 and 2021)
2019
Young plasma warned off
Ambrosia, a US startup, sold infusions of plasma, the liquid part of blood, from donors aged 16 to 25, for US$8,000 a liter in five states. Its registered study (NCT02803554), started in June 2016, enrolled 200 people in a single group, with no comparison group and no blinding, and posted no results. On 19 February 2019 FDA Commissioner Scott Gottlieb and Peter Marks, head of the agency's biologics center, said such infusions had "no proven clinical benefits" for the uses advertised, including aging, and carried risks. Ambrosia posted that it had "ceased patient treatments".
Lessona study with one group and no blinding cannot show whether a treatment does anything.
Credit
FDA; Ambrosia LLC
2020
Body scans measured from outside
Fabio Zugni and colleagues at the European Institute of Oncology in Milan pooled 12 studies covering 6,214 whole-body MRI scans of people with no symptoms. 95% of people had some abnormal finding, 30% had findings that needed further tests, and 1.1% had a cancer confirmed by biopsy. In April 2023 the American College of Radiology (ACR) said there was not enough evidence to recommend total-body screening for people without symptoms, risk factors or family history. A 2025 review in European Radiology of 10 studies and 9,024 people put confirmed cancers at 1.57%.
Lessonnearly every scan finds something, and few of the findings are cancer.
Credit
Zugni, Padhani, Koh, Summers, Bellomi and Petralia (Cancer Imaging); the ACR; João Martins da Fonseca and colleagues (European Radiology)
Watch for
Scans of 81,786 people
Prenuvo, a chain of whole-body MRI clinics, reported that of 81,786 people it scanned at 21 sites from January 2024 to June 2025, 61% had findings of some possible clinical relevance, 2.2% (1,776 people) had findings rated potentially or highly suspicious for cancer, and about 5% needed direct follow-up tests. The figures are the company's own, from a conference abstract for the 2026 meeting of the International Society for Magnetic Resonance in Medicine (ISMRM), and they do not say how many suspicious findings proved to be cancer.
Achieved whena group outside the company follows a scanned group of people and publishes confirmed cancers, false alarms, follow-up procedures and health outcomes, compared with similar people who were not scanned.
Claimed by
Prenuvo, posted August 2026
Open
01
Every clinic claim, checked
An open dataset of what longevity clinics sell. For each clinic: country, the regulator that licenses it, every service and claim on its website, published prices, and an archived copy of each page. For each claim: whether the test or treatment is approved for that use in that country, and the strongest human evidence found (randomized trial, other study, or none), coded by two people under published rules.
The briefCredit · unclaimed02
Written questions, asked openly
A study in which a researcher, writing under their own name, sends the same five questions to longevity clinics by email or contact form: which human study supports the clinic's main service; whether that service is approved for this use in the clinic's country; what side effects the clinic records and whom it reports them to; the full price; and which body licenses the clinic. The answers are scored against public records. No health details are given and nothing is bought.
The briefCredit · unclaimed
Open 01 · the brief
Every clinic claim, checked
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
An open dataset of what longevity clinics sell. For each clinic: country, the regulator that licenses it, every service and claim on its website, published prices, and an archived copy of each page. For each claim: whether the test or treatment is approved for that use in that country, and the strongest human evidence found (randomized trial, other study, or none), coded by two people under published rules.
Why it is still open
Published lists are small, scored by editors, or self-reported. Marco Demaria's 2025 editorial in Aging tabulates a few prominent, high-cost clinics and lists the table's limits, including "from" prices and clinics that present themselves as wellness providers. World Longevity Clinics, a commercial directory, gives 47 clinics in 18 countries an editorial score. A survey of 288 clinics run by two Dubai clinics reported that about 90% put marketing ahead of evidence, but its data are not published. A GitHub search for "longevity clinic" found clinic websites, not datasets.
pmc.ncbi.nlm.nih.govworldlongevityclinics.pages.devkhaleejtimes.com
Built with what exists
A web crawler such as Scrapy; the Internet Archive's Save Page Now to keep copies; the ClinicalTrials.gov API and regulators' approval databases (Drugs@FDA, the European Medicines Agency's medicine search) to check status; an open-weight AI model such as Mistral Large 4 to draft the list of claims from each page, which people then check (see the Note "A trillion open parameters").
First step
Archive the websites of the clinics in Demaria's table and of the centers licensed in Abu Dhabi, write the coding rules, and code ten clinics as a pilot.
Done looks like
At least 100 clinics in at least 10 countries and at least 1,000 coded claims, each linked to an archived page; a second coder repeats 10% of the claims and agrees on at least 90%; the data are released under an open license and refreshed every six months.
Open 02 · the brief
Written questions, asked openly
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A study in which a researcher, writing under their own name, sends the same five questions to longevity clinics by email or contact form: which human study supports the clinic's main service; whether that service is approved for this use in the clinic's country; what side effects the clinic records and whom it reports them to; the full price; and which body licenses the clinic. The answers are scored against public records. No health details are given and nothing is bought.
Why it is still open
Counts and directories of clinics have been built from their advertising. Turner and Knoepfler's 2016 study found stem cell sellers by internet keyword searches, and World Longevity Clinics scores clinics from public information. Searches this month found no published study that put the same written questions to longevity clinics and scored the replies.
Built with what exists
A protocol registered in advance on the Open Science Framework; ethics review where the researcher's institution requires it; a scoring rubric; a spreadsheet; an AI model to draft first-pass scores that two people check.
First step
Register the five questions and the rubric, and send them to ten clinics as a pilot.
Done looks like
At least 100 clinics in at least five countries contacted; the response rate reported; every reply scored by two people; the questions, rubric, scores and replies (with staff names removed) published.